Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo

Stine S. Jensen, Stine A. Petterson, Bo Halle, Charlotte Aaberg-Jessen, Bjarne W. Kristensen

Publikation: Bidrag til tidsskriftTidsskriftsartikelForskningpeer review

Abstract

Glioblastoma is the most frequent and most malignant brain tumor with the patients having a median survival of only 14.6 months. Although glioblastoma patients are treated with surgery, radiation and chemotherapy recurrence is inevitable. A stem-like population of radio- and chemoresistant brain tumor-initiating cells combined with the invasive properties of the tumors is believed to be critical for treatment resistance. In the present study, the aim was to investigate the effect of a novel therapeutic strategy using the lysosomotropic detergent siramesine on glioblastomas.
OriginalsprogEngelsk
Artikelnummer178
TidsskriftBMC Cancer
Vol/bind17
Udgave nummer1
ISSN1471-2407
DOI
StatusUdgivet - 7 mar. 2017

Fingeraftryk

Dyk ned i forskningsemnerne om 'Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo'. Sammen danner de et unikt fingeraftryk.

Citationsformater